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ABSTRACT 
Peroxisome proliferator-activated receptors gamma (PPARγ) are ligand-activated controllers 
of various metabolic actions and insulin sensitivity. PPARγ is thus considered as an important 
target to treat type 2 diabetes. Available PPARγ drugs (full agonists) have robust insulin-
sensitizing properties but are accompanied by severe side effects leading to complicated 
health problems. Here, we have used molecular docking and a molecular dynamics 
simulation study to find a novel PPARγ ligand from a natural product. Our study suggests 
that the inhibition of ceramicine B in the PPARγ ligand-binding domain (LBD) could act as a 
partial agonist and block cdk5-mediated phosphorylation. This result may provide an 
opportunity for the development of new anti-diabetic drugs by targeting PPARγ while 
avoiding the side effects associated with full agonists. 
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INTRODUCTION 
Peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear receptor, is highly 
expressed in adipose tissue and controls hundreds of genes to regulate diverse biological 
functions, which includes glucose metabolism, lipid metabolism, and insulin sensitivity [1]. 
PPARγ dynamically shuttles between the nucleus and cytoplasm, but after binding with the 
agonists, it forms a heterodimer with the retinoid X receptor (RXR) and co-activators. This 
heterodimer is then translocated to the nucleus, where it regulates target genes involved in 
different metabolic functions and improves insulin sensitivity. Consequently, PPARγ has 
been considered as a suitable drug target for the treatment of type 2 diabetes. 
Thiazolidinediones (TZDs), such as pioglitazone and rosiglitazone, which are full agonists of 
PPARγ, are highly effective for this purpose, and they effectively lower blood glucose levels 
[2-5]. Full agonists bind in pocket I of the LBD of PPARγ and form hydrogen bonds with the 
Ser289, His323, His449 and Tyr473 residues, leading to a conformational change of H12 in 
the LBD [6]. This remodeling of the LBD allows PPARγ to dock with transcriptional 
coactivators and results in its activation [7]. Unfortunately, the use of TZDs is also associated 
with undesirable side effects, such as fat accumulation, fluid retention, cancer, loss of bone 
density and an increased risk of heart failure [8-11]. As a consequence, TZDs are no longer 
recommended for the treatment of type 2 diabetes. This ensures the need for new selective 
PPARγ ligands with improved clinical profiles.  
Recent studies suggest that the obesity-induced CDK5-mediated phosphorylation of PPARγ 
at Ser245 (Ser273 for PPARγ2) results in the dysregulated expression of a series of genes 
associated with insulin resistance, which ultimately leads to diabetes [12, 13]. In the same 
study, it was also demonstrated that PPARγ ligands are capable of blocking this 
phosphorylation and are able to normalize the dysregulation of the PPARγ-target gene. These 
compounds (partial agonists) have a unique binding mode in the ligand-binding pocket of 
PPARγ. Current findings show that partial agonists bind in the region between H3, the Ω-
loop and the β-sheet, which form branch II of the PPARγ LBD, and that the region is 
different from the binding domain of a PPARγ full agonist. Most of the partial agonists 
interact via hydrogen bonding with Ser342 and via several hydrophobic interactions with the 
residues of branch II of the LBD of PPARγ, which causes the stabilization of the β-
sheet/Ser245 surface and blocks phosphorylation. This mechanism exhibits antidiabetic 
effects similar to those of full agonists through the inhibition of PPARγ while ameliorating 
the side effects caused by the PPARγ transcriptional activity [12, 14, 15].  Until now, a 
number of PPAR𝛾 partial agonists have been reported, but none of them are currently FDA 
approved [16-21].  A few of these partial agonists have progressed through Phase II clinical 
trials, and several have not yet been tested for the later phases. Additionally, it has been 
reported that partial agonists exhibit a certain amount of transcriptional activation [21]. Thus, 
investigation on a new kind of partial agonist merits an intensive research focus. 
Here, we have examined the agonist activity of ceramicines A–L (Figure 1) on PPAR𝛾 using 
molecular docking and a molecular dynamics simulation study. Ceramicine is similar in size 
to most of the other PPAR𝛾 partial agonists [19, 22], as it consists of a phenanthrene ring 
with a large variation of moieties at different positions, and both cyclopentane and furan ring 
systems (Figure 1). A recent experimental study suggests that ceramicine B acts as an anti-
lipid droplets accumulation agent by interrupting the phosphorylation of FoxO1, which leads 
to the down regulation of the transactivation activity of PPARγ [22]; furthermore, studies on 
partial agonists reveal that the PPARγ activation by an H12-independent mechanism 
subsequently decreases the transcriptional activity of PPARγ [14, 15]. Examination of the 
binding affinity of ceramicine B and other ceramicines in the PPARγ ligand binding pocket 
would therefore be of great interest. Additionally, a large variation of moieties could allow 
for different binding possibilities in the LBD of PPARγ. 
 Figure 1: The molecular structure of ceramicine A-L. 
RESULTS AND DISCUSSION              
Molecular docking analysis 
In this study, we have examined the binding affinities of ceramicines A–L, Chelerythrine and 
SR1664 (Figure 1) using the AutoDock4 molecular docking program. Molecular docking is a 
computational method that performs the virtual screening of drug-like compounds based on 
target structures and identifies appropriate confirmations with a binding affinity score. This 
gives the fastest and most accurate prediction of drug-like candidates for a target protein and 
allows for further biological testing. Twelve ceramicine compounds (A to L) are known to 
originate from the bark of Malaysian C. ceramicus [23-26].  The docking of these 12 
ceramicines shows four minimum energy poses in the LBD of PPARγ depending on the 
position of the moiety. Ceramicines B and D have similar lower binding energy 
conformations (docking pose 1, Figure 2A), with binding energies of -9.2 kcal/mol and -9.24 
kcal/mol, respectively, filling branch II of the ligand binding pocket. The hydroxyl group at 
position 7 for both ceramicines B and D forms hydrogen bonds with the NH group of the 
Ser342 residue of the β-sheet, which is the key residue for partial agonist activation. These 
two molecules are also involved in several hydrophobic interactions with the residues of the 
H3, β-sheet and Ω-loop region (Figure 2A). Interactions of ceramicines B and D with PPARγ 
indicate that changes in the furan ring by furanone do not make a significant difference in the 
binding affinity of ceramicine. 
 
 
  
Figure 2: Left: The local structure of the docking complexes for ceramicine molecules in 
PPARγ LBD. (A) Ceramicine B and D (B) Ceramicine C, H and I (C) Ceramicine L, F and G 
(D) Ceramicine A, E and K. Right: Hydrophobic and hydrogen bond contacts between 
PPARγ protein and ceramicine compound determined by LIGPLOT program (A) Ceramicine 
B (B) Ceramicine C (C) Ceramicine G (D) Ceramicine A. 
 
Ceramicines C, H and I have a methacrylate, a tiglate and an acetate moiety, respectively, at 
position 12. The substitution of an α-H at this position of ceramicine B by an ester group 
moiety leads to a conformational change in the ceramicine binding pose (docking pose 2, 
Figure 2B), as all these moieties form hydrogen bonds with the NH group of Ser342. The 
length of the hydrogen bond involved for ceramicines C, H and I are 2.74 Å, 2.75 Å and 2.82 
Å, respectively. Hydrophobic contacts are formed with the residues of H3, H5, H6 and the β-
sheet region, which allow the mentioned ceramicines to occupy branch II with the best 
binding conformations at energies of -9.53 kcal/mol, -9.89 kcal/mol, and -8.77 kcal/mol, 
respectively. Ceramicines B, C, D, H and I are all aligned parallel to the β-sheet in the LBD 
of PPARγ. While ceramicines B and D exhibit more hydrophobic interactions towards H3 
and the Ω-loop, ceramicines C, H and I make hydrophobic contact with the residues of H5 
and H6. None of these ceramicines are involved with the H12 residue in domain I of the 
binding pocket. 
Substitutions by aldehyde, methoxycarbonyl, acetate and hydroxyl groups at positions 4 and 
6 increase the polar surface in the phenanthrene ring of ceramicine and allow different 
binding conformations for ceramicines A, K, L, F and G in the binding pocket. Figure 2C 
illustrates the lowest energy docking poses of ceramicines L, F and G, which shows that the 
moiety in the phenanthrene ring interacts with the HIS323, TYR327, SER89, CYS285, 
ARG288 residues of branch I, maintaining hydrogen bonds with the CYS285 and GLY284 
residues. The furan ring of these ceramicines reaches the β-sheet region of the LBD and 
forms hydrophobic interactions with the MET348, ILE341 and SER342 residues. The lowest 
binding energy conformations of ceramicines L, F and G have binding energies of -7.75 
kcal/mol, -8.36 kcal/mol, and -8.7 kcal/mol, respectively. Conversely, the hydroxyl and 
acetate moiety at position R1 of ceramicines A and K forms hydrogen bonds with Cys285 
and hydrophobic interactions with the residues of H11, H5, H7 and H3. The lowest energy 
docking pose spreads from the branch I to branch III of the LBD, as shown in Figure 2D. 
This is typical for the interaction of the PPARγ full agonist in the binding pocket. Ceramicine 
E (Figure 1) also shows the same binding conformations in the pocket. A similar 
conformation was again observed when cyclopentane was substituted by a cyclopentanone in 
ceramicine J.  
The docking simulation study of the ceramicines in the LBD of PPARγ reveals that the 
position of the moiety in the phenanthrene ring, cyclopentane ring and furan ring is important 
in determining the binding conformation of ceramicine. Moiety variation in a particular 
position does not make much difference in the docking pose of the ligand; therefore, one 
ceramicine-PPARγ complex for each docking pose involved in partial agonist activity with 
the simplest ceramicine moiety and best binding affinity (ceramicine B, C and G) has been 
considered for further study. 
We next evaluated the ADMET properties of ceramicine B, C and G by means of the 
Lipinski rule [27] using the FAFDrugs3 server [28]. The different parameters predicted were 
molecular weight, number of hydrogen bond donors and acceptors, topological PSA, number 
of rotatable bonds and log P. The ADMET parameters of the compounds are shown in 
Supplementary Table S1, which reveals that the values of the descriptors are within the 
optimum range followed by drug molecules. All three ceramicine compounds satisfied the 
Lipinski rule of five and were thus considered for the subsequent molecular dynamics 
simulation studies, which were performed to obtain the orientations of the compounds at the 
active site under dynamic conditions. 
Molecular dynamics simulation analysis 
A molecular dynamic study has been performed for the lowest energy conformations of 
ceramicines B, C and G. The best docking poses of these ceramicines in the docking 
simulation illustrate that they interact with the residues of branch II of the ligand binding 
pocket of the PPARγ target protein(PDB ID: 2F4B), which is similar to other partial agonists 
reported in previous studies [16-18]; however, the docking simulation only provides a static 
interaction mode of the protein-ligand complex. To investigate the protein-ligand interaction 
stability under dynamic conditions, a 100ns molecular dynamics simulation for the protein-
ligand complexes has thus been performed and compared with the dynamic behavior of the 
uncomplexed PPARγ protein.  
 
Figure 3: The RMSD value of the Cαatoms during 100 ns simulation of PPARγ(red), PPARγ 
-ceraicine G(blue), PPARγ -ceraicine C (green) and PPARγ -ceraicine B (black) system. 
The RMSD is an important parameter used to differentiate the conformational stability of 
protein systems from MD simulation. The RMSD of Cαatoms (Cα-RMSD), with respect to 
the structure present in the energy minimized, equilibrated system for each simulation, and 
has been calculated as a function of time. The plot in Figure 3 describes the Cα-RMSD of the 
complexed and uncomplexed PPARγ protein during the 100-ns simulation. In Figure 3, it is 
clear that the Cα-RMSD of all the PPARγ-ceramicine complexes equilibrated before 20 ns, 
whereas uncomplexed PPARγ took 40 ns to stabilize during simulation. The Cα-RMSD of 
PPARγ bound with ceramicine G exhibited a constant deviation of ~0.38 nm after reaching 
the equilibrium state. In the case of the uncomplexed PPARγ and the PPARγ-ceramicine C 
complex, the RMSD equilibrated with slightly lower values of ~0.35 nm and 0.33 nm, 
respectively. The Cα-RMSD for the PPARγ-ceramicine B complex had a smaller fluctuation 
than all the other considered systems. The PPARγ structure is therefore more stable when 
complexed with ceramicine B. 
 
Figure 4: RMSF of Cα atoms as a function of amino acids for PPARγ(red), PPARγ -ceraicine 
G(blue), PPARγ -ceraicine C (green) and PPARγ -ceraicine B (black) system. 
To investigate the dynamics of the important residues in the complexes compared to the 
uncomplexed form, the root mean square fluctuations (RMSF) of the rCα atoms of the protein 
were calculated, as shown in Figure 4.The figure represents reduced RMSF values for H3 and 
the β-sheet when complexed with ceramicine B relative to other considered complexes. The 
displacement of the H12 residue of the PPARγ-ceramicine B complex is comparable to that 
of the uncomplexed form, whereas in the inhibition of ceramicine C, ceramicine G highly 
stabilizes helix 12; thus, RMSF variation shows that ceramicine B stabilizes the H3, β-sheet 
and Ser245 regions more strongly than the other ceramicines, which could indicate more 
efficiency in blocking the Cdk5-mediated phosphorylation of Ser245 [29]. Conversely, the 
dynamics of H12 remain unaffected due to the inhibition of ceramicine B, which reflects the 
transcriptional activity-independent inhibition of PPARγ [14, 15].Hence, ceramicine B could 
act as the most significant PPARγ partial agonist in comparison to other ceramicines. 
 
  
Figure 5: Final nanosecond snapshots of (A) Ceramicine B (B) Ceramicine C (C) 
Ceramicine G in PPARγ LBD obtained from molecular dynamics simulation. Residues with 
thick bond are making hydrogen bond interaction during the course of the simulation.  
 
  
Figure 6: Number hydrogen bonds formed between residues of PPARγ and Ceramicine B 
(A), Ceramicine C (B), Ceramicne G (C) during the simulation.  
 To understand the interaction of ceramicines with PPARγ during the course of the simulation, 
the number of hydrogen bonds formed with different residues of the LBD has been calculated 
(Figure 6), and the pdb file at 100ns has been taken out to check the final confirmation of the 
inhibitor in the binding pocket. Figure 5 depicts the final binding modes of ceramicines B, C 
and G, which shows that all the ceramicines moved from their static docking poses during 
simulation due to the lack of constant hydrogen bond interactions with particular residues 
(Figure 6). Ceramicines C and G maintain their conformations, similar to other reported 
partial agonists [16, 17], and hydrogen bonding with Ser342 is significantly lower. 
Ceramicine C forms the maximum number of hydrogen bond contacts with Arg288, and 
ceramicine G forms the maximum number with Gly284. Ceramicine B, however, exhibits a 
different binding conformation previously not reported for any other partial agonist. After 
few nanoseconds of the simulation, ceramicine B moved to the position in (shown in Figure 
5) which it forms hydrogen bonds with Ser342 and Gln345, and its furan ring forms a π–π 
stacking interaction with Phe247.Additionally, ceramicine B maintains a greater number of 
hydrogen bond contacts with Ser342 during the simulation in comparison to the other 
ceramicines. Thus, the new binding conformation of ceramicine B could be an effective 
PPARγ partial agonist, as it highly stabilizes the β-sheet/Ser245 region but does not affect the 
dynamics of H12. 
CONCLUSIONS 
Our results demonstrate that different ceramicines from the bark of Malaysian C. ceramicu 
exhibit different binding conformations in the PPARγ LBD depending on the position of the 
moiety. Ceramicines have the shape and volume that fit into the region where partial agonists 
typically bind and moiety to bind with Ser342. This is particularly important because large 
ligands that occupy branch-II also spread towards branch-I and interact with helix 12.The 
docking simulation study shows that ceramicines B (D), C (H, I) and G (L, F) bind in a 
manner that could act as PPARγ partial agonists and that the lowest energy conformations of 
ceramicines B, C and G engage in H12-independent interactions. Further investigations using 
MD simulations suggest that ceramicine B constructs hydrogen bonds with the residues of the 
β-sheet and reduces the dynamics of the residues around the Ser245 region, keeping H12 
unaffected, whereas other ceramicines altered the H12 dynamics with a lower number of 
hydrogen bond interactions with theβ-sheet region. Thus, our finding shows a new binding 
conformation of an inhibitor (ceramicine B) in the LBD of PPARγ that significantly stabilizes 
the Ser245 region and could block Ser245 phosphorylation. A lower degree of H12 
stabilization, which affects the recruitment of co-activators, decreases the transcriptional 
activity of PPARγ. Additionally, ceramicines show good ADMET properties that are within 
the optimum range of orally active drugs; furthermore, our results provide a new active 
molecule from natural extracts with antidiabetic properties that acts through the inhibition of 
Cdk5-mediated phosphorylation of PPARγ while lacking classical agonism. 
MATERIAL AND METHODS 
Data set 
The crystal structures of the PPARγ (isoform 1) receptor protein of Protein Data Bank (PDB) 
ID 2F4B [30] were downloaded from RCBS Protein Data Bank (http://www.pdb.org). The 
bound ligand and unwanted atoms were removed from the protein structure and minimized 
using the GROMACS-4.5.6 software package [31]. The 3D structures of ceramicines A–L 
were generated by using CORINA software, (https://www.molecular-networks.com/), which 
takes Isomeric SMILES from the Pubchem compound database 
(http://www.ncbi.nlm.nih.gov/pccompound), and the structure was optimized with the help of 
Chimera 1.6.2. 
Molecular docking and virtual screening 
The docking study of the considered molecules into the PPARγ active site was performed 
with AutoDock4 [32]. AutoDock is one of the most widely used docking software programs 
that uses a Lamarckian genetic algorithm to predict the docking conformation between 
protein and ligand [33].  AutoDock Tools 1.5.6 was employed to prepare the protein and 
ligand and to perform the docking simulation. During the docking process, the protein was 
kept rigid and the ligands were flexible with all their torsional bonds free to rotate. A cubic 
grid box of size 60 Å×60Å×60 Å with points separated by 0.375 Å was generated and 
encompassed all the active site residues of PPARγ. All the default parameters were applied 
except the number of GA runs, which was set to 100.At the end of each docking, the lowest 
energy conformation was considered as the best binding conformation between each 
considered molecule and PPARγ. Cluster analysis showed that more than 20 percent of 
docking poses had the lowest energy conformations in each docking study.  
The FAF Drugs3 web server [28] was used to analyze the ADMET properties of the best-
docked ceramicine compounds obtained from the AutoDock result. ADMET properties play 
an extremely crucial role in the discovery and development of novel drugs at the earlier stage, 
as unfavorable ADMET properties have been identified as a major cause of failure even for 
the most promising drug candidate molecules [34]. While calculating these properties using 
the FAFDrugs3 server, all the filtering options were kept as default except the ―logP 
computation program‖ and ―physchem filters‖, which were set as ―XLOGP3‖ and ―Lipinski-
RO5‖, respectively. According to this, the ligands were screened by Lipinski’s rule of five, 
which suggests that compounds are within the acceptable range for a drug molecule if they 
possess a logP of less than 5, a molecular weight of less than 500, fewer than ten rotatable 
bonds and no more than 5 hydrogen-bond donors and ten hydrogen-bond acceptors. 
Molecular dynamic simulation 
The molecular dynamics simulations of the PPARγ protein and previously screened PPARγ-
ceramicine complexes were performed using GROMACS-4.5.6 software [35] under the 
GROMOS96 53a6 force field [36, 37].The topology files of ceramicine compounds were 
generated using the online Automated Topology Builder (ATB) server, which applies 
quantum mechanical calculations combined with a knowledge-based approach to derive the 
GROMACS compatible force field parameters [38]. All the complexes were handled 
separately by putting them into a cubic box and were solvated by using the SPC216 water 
model. Na ions were added to each system to electrically neutralize the total charge by using 
the genion tool of the GROMACS package, which randomly substitutes water molecules with 
ions at the most favorable electrostatic potential positions. This was followed by energy 
minimization using a steepest decent algorithm with a maximum step size of 0.01 nm, 
maintaining a tolerance of 1000 kJ/mol/nm. The system was then subjected to equilibration at 
300 K and 1 bar for 100ps under the conditions of position restraints for heavy atoms and 
LINCS constraints for all bonds [35]. Finally, the full system was subjected to a 100 ns MD 
simulation run, and the corresponding atom coordinates were stored every 0.002 ps during 
the simulation for later analyses. 
ABBREVIATIONS 
PPARγ: Peroxisome proliferator-activated receptors gamma; Ser: Serine; Cdk5: Cyclin-
dependent kinase 5; Gly: Glycine; TZDs: Thiazolidinediones; LBD: ligand-binding domain; 
ADMET: Absorption, Distribution, Metabolism, Excretion and Toxicity; RCBS: Research 
Collaborators for structural Bioinformatics Protein; RMSD: Root-Mean-Square Deviation;  
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SUPPLEMENTARY FILE 
 
Table1. ADMET properties of ceramicine B, C and G as predicted by 
FAFDrugs3 server (Lagorce et al., 2015). 
Parameters Ceramicine B Ceramicine C Ceramicine G Chelerythrine 
Molecular Weight (g/mol) 408.53 492.60 454.56 348.37 
HBD 1 1 2 0 
HBA 4 6 6 5 
Topological PSA (Å2) 59.67  85.97 96.97 40.80 
Rotatable Bonds 1 4 3 2 
logP 3.94 4.14 3.22 4.58 
Lipinski Violations 0 0 0 0 
 
 
 
 
 
